VAM
ICPT

Visium Asset Management’s Intercept Pharmaceuticals, Inc. ICPT Stock Holding History

Visium Asset Management’s Portfolio ICPT Stock Details ICPT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q3 		– Sell
-19,800
Closed -$2.83M – 210
2016
Q2 		$2.83M Buy
+19,800
New +$2.89M 0.2% 133

Other funds holding ICPT

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
CG
Carmignac Gestion Paris, France $6.51B AUM 19.13% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.14% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.26% 1-Year Est. Return

Visium Asset Management's ICPT Position: Q2 2016 in Review

Visium Asset Management sold out of Intercept Pharmaceuticals, Inc. (ICPT) in Q2 2016, closing a stake of 30,684 shares — an estimated $4.47M sold.

Visium Asset Management first reported a position in ICPT in Q2 2013 and held it in 5 quarters. The position peaked at $52.9M in Q3 2013. 167 funds tracked by Wall St. Rank hold ICPT as of Q2 2016.

  • Visium Asset Management reported no remaining Intercept Pharmaceuticals, Inc. position as of Q2 2016 after selling out during the quarter.
  • Visium Asset Management sold 30,684 Intercept Pharmaceuticals, Inc. shares in Q2 2016, an estimated $4.47M.
  • Visium Asset Management first reported a position in Intercept Pharmaceuticals, Inc. in Q2 2013 and held it in 5 quarters.
  • Visium Asset Management's Intercept Pharmaceuticals, Inc. position peaked at $52.9M in Q3 2013.
  • 167 funds tracked by Wall St. Rank held Intercept Pharmaceuticals, Inc. as of Q2 2016.

Based on Visium Asset Management's 13F filing for Q2 2016, filed 12 Aug 2016.